Clinical Trials Logo

Clinical Trial Summary

What happens in the borderzone of a cerebral hemorrhage remains widely onknown and furhter the best timing for doing MR to look for vascular pathology in cerebral hemorrhage has not yet been determined. In this study we do acute MRS, a non-invasive imaging mathod to detemine the biochemsty in the border zone and structural MRI for vascular malformation. We repeat structural MRI after 8 weeks.


Clinical Trial Description

In this study we want to investigate the ability of MRI to identify underlying pathology (tumor or vascular malformations) in acute patients admitted with intracerebral hemorrhage (ICH). Today MRI-scan is normally done 3-4 weeks after symptom onset but very little is known about the early use of MRI to detect underlying pathology. This would allow an early intervension and less uncertainty for the patients. We further want to investigate the metabolic penumbra-zone surrounding the hematoma. It is the current perception in the litterature that this zone represent a metabolic zone marked by apoptosis and inflammation rather than ischemia. We are planning to: When patients arrive in our stroke department they will within 7 hours be subject to MRI scan with the protocoled sequences. Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence. Susceptibility weighted imaging (SWI) Chemical Shift Imaging (CSI) multivoxel spectroscopi Post contrast 3D box reconstruction After 8 weeks the patients are subject to another MRI-Scan in accordance with the standard clinical guideline to rule out underlying pathology. After 3 month the patients are seen in the outpatient-clinic to follow-up evaluation. To sum up the purpose of this present study is to conduct a pilot investigation of MRI in the early evaluation of ICH-patients. Second it is our intension to use multivoxel magnetic resonance spectroscopy to study the metabolic penumbra-zone surrounding the ICH. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01689402
Study type Observational
Source Bispebjerg Hospital
Contact
Status Completed
Phase
Start date April 2012
Completion date May 2017

See also
  Status Clinical Trial Phase
Completed NCT02810899 - Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Phase 4
Withdrawn NCT00977795 - A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors Phase 1/Phase 2
Recruiting NCT00787982 - Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors Phase 1/Phase 2
Withdrawn NCT00555984 - Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors N/A
Completed NCT00038441 - Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas Phase 1/Phase 2
Recruiting NCT03619694 - Role of MR Spectroscopy in Brain Tumors
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Unknown status NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT01244737 - FLT-PET Imaging of Brain Tumors in Children Phase 2
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Terminated NCT00769093 - Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy Phase 1
Completed NCT00392119 - MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors Phase 1
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Terminated NCT00038389 - Study of Vioxx and Radiation Therapy for Brainstem Glioma Phase 1
Recruiting NCT05049148 - Platelets Activation in Brain Neoplasms N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT04712721 - Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Early Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Terminated NCT01954576 - NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A
Recruiting NCT05538130 - A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors Phase 1